Entry Name Leflunomide (JAN/USP/INN);
Product Generic LEFLUNOMIDE (A-S Medication Solutions) ,
LEFLUNOMIDE (Alembic Pharmaceuticals Limited) ,
LEFLUNOMIDE (Alembic Pharmaceuticals) ,
LEFLUNOMIDE (Apotex Corp.) ,
LEFLUNOMIDE (Aurobindo Pharma Limited) ,
LEFLUNOMIDE (AvKARE) ,
LEFLUNOMIDE (AvPAK) ,
LEFLUNOMIDE (Bryant Ranch Prepack) ,
LEFLUNOMIDE (Bryant Ranch Prepack) ,
LEFLUNOMIDE (Burel Pharmaceuticals) ,
LEFLUNOMIDE (Chartwell RX) ,
LEFLUNOMIDE (Fosun Pharma USA) ,
LEFLUNOMIDE (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals) ,
LEFLUNOMIDE (Lupin Pharmaceuticals) ,
LEFLUNOMIDE (Winthrop U.S) ,
LEFLUNOMIDE (Zydus Lifesciences Limited) ,
LEFLUNOMIDE (Zydus Pharmaceuticals (USA)) Formula C12H9F3N2O2
Exact mass 270.0616
Mol weight 270.2073
Structure Mol file KCF file DB search Simcomp Neighbor Class Anti-inflammatoryDG01985 Disease modifying anti-rheumatic drug (DMARD)DG01633 CYP3A/CYP3A4 substrateDG02913 CYP3A4 substrateDG01643 CYP2C9 inhibitor Remark Therapeutic category: 3999
Efficacy Antirheumatic, Dihydroorotate dehydrogenase inhibitor
Disease Active rheumatoid arthritis [DS:
H00630 ]
Comment Antineoplastic (blocks PDGF receptor function, inhibiting the growth and survival of human tumor cells when administered intravenously), Used in the treatment of rheumatoid arthritis when administered orally
Target Pathway Metabolism Enzyme: CYP3A4 [HSA:
1576 ]
Interaction CYP inhibition: CYP2C9 [HSA:
1559 ]
DDI search Structure map map07050 Antirheumatics - DMARDs and biological agents
Brite Anatomical Therapeutic Chemical (ATC) classification [BR:br08303 ]br08302 ]br08301 ]br08330 ]br08332 ]br08310 ]br08329.html ]br08318.html ]br08309.html ] BRITE hierarchy Other DBs KCF data Show
